Curative efficacy of cyclophosphamide combined with VAD regimen in treatment of multiple myeloma and its effects on coagulation function
10.3969/j.issn.1005-1678.2017.03.083
- VernacularTitle:环磷酰胺联合VAD方案治疗多发性骨髓瘤的临床效果及对患者凝血功能的影响
- Author:
Yongping XU
;
Gang CHEN
;
Qin ZHANG
- Keywords:
cyclophosphamide;
VAD regimen;
multiple myeloma;
clinical effect;
coagulation function
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(3):267-269
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study curative efficacy of cyclophosphamide combined with VAD regimen in treatment of multiple myeloma and its effects on coagulation function.Methods 78 patients of multiple myeloma who received therapy from July 2013 to July 2016 in our hospital were selected as research objects, and divided into the control group and the observation group , the control group was treated with VAD regimen, while the observation group was treated with cyclophosphamide combined with VAD regimen.Then coagulation factor and anti-coagulation factor activity, adverse reaction, therapeutic effect after treatment between two groups were compared.Results After treatment, decreased blood coagulation factor, Protein C, protein S and antithrombin were increased between two groups , the difference was not statistically significant.Incidence of adverse reactions in observation group was less than the control group[15.38%(6/39)vs 46.15%(18/39)], the difference was statistically significant(P<0.05);The total effective rate of observation group was statistically higher than that in the control group [ 89.74%( 35/39 ) vs 58.97%( 23/39 ) ] , the difference was statistically significant(P<0.05).Conclusion Cyclophosphamide combined with VAD regimen is well for multiple myeloma, which can effectively improve the patient's condition, improve the life quality of patients, and will not cause a greater impact on blood coagulation function.
